{
  "id": 9182308,
  "title": "Amgen reports a Phase 3 win with Sjögren’s drug candidate",
  "url": "https://urgent.news/2026/09/22/amgen-reports-a-phase-3-win-with-sjogrens-drug-candidate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T18:31:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/amgen-dazodalibep-sjogrens-syndrome-study-results/831042/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal",
        "url": "https://urgent.news/2026/09/22/amgens-phase-3-sjogrens-win-novartis-900m-radioligand-deal",
        "published": "2026-09-22T15:29:54.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}